Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Jessica Koffel
EU Pharma Reform – We Have A Deal! | JD Supra
On 11 December 2025, the European Union (EU) institutions reached an agreement on the “Pharma Package”. This milestone follows several years of legislative work, beginning with the European Commission’s proposal in April 2023, which initiated the most substantial update to EU pharmaceutical legislation in more than two decades.
EMA Adopts Revised CTIS Transparency Rules
On 5 October 2023, the European Medicines Agency (EMA) adopted revised transparency rules for the publication of information on clinical trials submitted through the Clinical Trials Information System (CTIS). The CTIS plays a fundamental role in facilitating the exchange of clinical trial information within the European Union (EU), as provided in the Clinical Trials Regulation (CTR).
EMA Adopts Revised CTIS Transparency Rules | JD Supra
On 5 October 2023, the European Medicines Agency (EMA) adopted revised transparency rules for the publication of information on clinical trials submitted through the Clinical Trials Information System (CTIS). The CTIS plays a fundamental role in facilitating the exchange of clinical trial information within the European Union (EU), as provided in the Clinical Trials Regulation (CTR).
EMA Adopts Revised CTIS Transparency Rules
On 5 October 2023, the European Medicines Agency (EMA) adopted revised transparency rules for the publication of information on clinical trials submitted through the Clinical Trials Information System (CTIS). The CTIS plays a fundamental role in facilitating the exchange of clinical trial information within the European Union (EU), as provided in the Clinical Trials Regulation (CTR).
EU Study Investigates Different Models For Directly Shipping Drugs To Patients
On 12 July 2023, a study was published in the British Journal of Clinical Pharmacology on different models in Europe for directly shipping drugs to patients during decentralized clinical trials (DCTs ), which are conducted in environments such as a participant's home or a local address, rather than investigative sites.
EU Study Investigates Different Models for Directly Shipping Drugs to Patients
Although the European Union lacks harmonised requirements related to the shipping of IMPs directly to study participants, trial sponsors have been experimenting with different approaches. DtP supply of IMPs and DCT models were important to on-going activities related to clinical trials conducted during the COVID-19 pandemic. Previous research already suggested that EU law would not prohibit home shipping or administration of medicinal products for use in conducting a clinical trial.
European Commission Adopts Directive Extending Time Lead Can Be Used In PVC Sensors Of IVDs
The European Commission has adopted Commission Delegated Directive (EU) 2023/1526, which amends Directive 2011/65/EU of the European Parliament and European Council as regards an exemption for lead as a thermal stabilizer in polyvinyl chloride (PVC) used as base material in sensors for in vitro diagnostic medical devices (IVDs).
European Commission Adopts Directive Extending Time Lead can be used in PVC sensors of IVDs
The European Commission has adopted Commission Delegated Directive (EU) 2023/1526, which amends Directive 2011/65/EU of the European Parliament and European Council as regards an exemption for lead as a thermal stabilizer in polyvinyl chloride (PVC) used as base material in sensors for in vitro diagnostic medical devices (IVDs).
European Commission Publishes Guidance On Transition From Clinical Trials Directive To Clinical Trials Regulation
On 19 July 2023, the European Commission published a guidance document concerning the steps to be taken in the transition of clinical trials from the Clinical Trials Directive (CTD) to the Clinical Trials Regulation (CTR). On 19 July 2023, the European Commission published a guidance document concerning the steps to be taken in the transition of clinical trials from the Clinical Trials Directive (CTD) to the Clinical Trials Regulation (CTR).
European Commission Publishes MDR And IVDR Factsheet For Non-EU/EEA Countries
On 12 July 2023, the European Commission published a factsheet for authorities outside the European Union (EU) and the European Economic Area (EEA) on the implications of the extended deadlines inRegulation (EU) 2017/745 on medical devices(MDR) and Regulation (EU) 2017/746 on in vitro diagnostic medical devices (IVDR). On 15 March 2023, the MDR and IVDR were amended with deadlines extended beyond the originally established date of 26 May 2024.
UK Government Provides Limited Extensions To Recognition Of CE Marks For Medical Devices In Great Britain - Healthcare - UK
On 1 August 2023, the UK government announced plans to extend recognition of CE marking 'indefinitely' for certain products placed on the Great Britain market (England, Wales and Scotland). However, medical devices are not among the categories of products concerned by the indefinite recognition of CE marking. Instead, the UK government has been working to introduce regulations to substantially reform the current regulatory framework governing medical devices in the UK.
GCP Q&A Clarifies Sponsor Role In Trial-Related Tasks, Provides Other Updates
The European Medicines Agency (EMA) has updated its Q&A for good clinical practice (GCP). The update acknowledges that the sponsor may support the investigator by identifying or contracting service providers in the conduct of the clinical trial. This update reflects the leading role of sponsors in interaction with contracting service providers when trial activities are conducted remotely during decentralized clinical trials (DCTs).
GCP Q&A Clarifies Sponsor Role in Trial-Related Tasks, Provides Other Updates
The European Medicines Agency (EMA) has updated its Q&A for good clinical practice (GCP). The update acknowledges that the sponsor may support the investigator by identifying or contracting service providers in the conduct of the clinical trial. This update reflects the leading role of sponsors in interaction with contracting service providers when trial activities are conducted remotely during decentralized clinical trials (DCTs).
European Commission Publishes Proposals to Revise Current EU Pharmaceutical Legislative Framework | JD Supra
Yesterday, the European Commission published two legislative proposals concerning the regulation of medicinal products in the European Union. The proposals seek to consolidate existing legislation into two instruments, a revised and amplified version of Directive 2001/83, the Community code on medicinal products, and a revised and amplified version of Regulation 726/2004, the European Medicines Agency (EMA) Regulation.
European Commission Publishes Proposals to Revise Current EU Pharmaceutical Legislative Framework
Yesterday, the European Commission published two legislative proposals concerning the regulation of medicinal products in the European Union. The proposals seek to consolidate existing legislation into two instruments, a revised and amplified version of Directive 2001/83, the Community code on medicinal products, and a revised and amplified version of Regulation 726/2004, the European Medicines Agency (EMA) Regulation.
European Medicines Agency Publishes Q&A on Clinical Trial Data Transparency
Following the entry into application of the Clinical Trials Regulation (EU) 536/2014 (CTR) for all initial clinical trial applications on 31 January 2023, the European Medicines Agency (EMA) has published a Q&A document concerning the transparency obligations established in the CTR in relation to information submitted in support of an application.
European Commission Publishes Updated Q&A on Clinical Trials Regulation
In December 2022, the European Commission published an updated version of the Q&A guidance on the Clinical Trials Regulation (CTR). This new version was issued ahead of the 31 January 2023 deadline from which all new applications for the approval of clinical trials must be submitted in accordance with the CTR. The most important amendment to the Q&A is the inclusion of a new Annex III. The application dossier for the approval of a clinical trial in accordance with the CTR is composed of two parts.
European Commission Proposes Amending Transitional Provisions in Medical Devices and In Vitro Diagnostics Regulations | JD Supra
On 6 January 2023, the European Commission adopted a proposal to amend the transitional provisions of Regulation (EU) 2017/745 on medical devices (MDR) and Regulation (EU) 2017/746 on in vitro diagnostic medical devices (IVDR). The proposal aims to prevent medical device shortages on the European Economic Area (EEA) market.
European Commission Proposes Amending Transitional Provisions in Medical Devices and In Vitro Diagnostics Regulations
On 6 January 2023, the European Commission adopted a proposal to amend the transitional provisions of Regulation (EU) 2017/745 on medical devices (MDR) and Regulation (EU) 2017/746 on in vitro diagnostic medical devices (IVDR). The proposal aims to prevent medical device shortages on the European Economic Area (EEA) market.
European Commission publishes updated Q&A on the Clinical Trials Regulation
In December 2022, the European Commission published an updated version of the Q&A guidance on the Clinical Trials Regulation (“CTR”). This new version was issued shortly ahead of the 31 January 2023 deadline from which all new applications for the approval of clinical trials must be submitted in accordance with the CTR. The most important amendment to the Q&A is the inclusion of a new Annex III.
European Commission Proposes Extending Transition Period Foreseen in Medical Devices Regulation
The implementation of Regulation (EU) 2017/745 on medical devices (MDR) was discussed on the second day of the meeting of the Employment, Social Policy, Health and Consumer Affairs Council (EPSCO) on 9 December 2022.
Medical Devices Regulation - Life Sciences, Biotechnology & Nanotechnology - European Union
The EU Medical devices Regulation Cooley's Productwise Bitesize brings you a short overview of the EU Medical Devices Regulation. What is it called? The Medical Devices Regulation (MDR Regulation (EU) 2017/745) governs the placing on the market in the European Economic Area (EEA) of medical devices and its accessories as well as clinical investigations taking place in the EEA.
European Union February 4 2022 On 14 January 2022, the European Commission published a draft Implementing Regulation laying down the Common Specifications for the groups of products without an intended medical purpose that are listed in Annex XVI of the Medical Device Regulation (“MDR”). The proposal would establish technical and clinical requirements that these products must fulfil to demonstrate compliance with the MDR.
Productwise Bitesize: Clinical Trials Regulation
To print this article, all you need is to be registered or login on Mondaq.com. The EU Clinical Trials Regulation's transitional period Cooley's Productwise Bitesize brings you a short overview of the transitional provisions in the new Clinical Trials Regulation. What is it called? On 31 January 2022, Regulation (EU) 536/2014 on clinical trials on medicinal products for human use (the “Clinical Trials Regulation”) will become applicable in the EU.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Jessica
Contact Jessica, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack